West Pharmaceutical Services

President Trump purchased between $680,000 and $1.18 million in stock in Eli Lilly and West Pharmaceutical Services in early 2025, shortly before the administration implemented policies that significantly benefited these companies, including advancing Medicare reimbursement for GLP-1 drugs and cracking down on cheaper generic competitors. Government ethics experts have raised concerns that the stock purchases undermine public trust by creating the appearance that Trump is personally profiting from administration actions. Congressional Democrats are calling for legislation to ban presidents from owning and trading stocks.

President Donald Trump bought stock in Eli Lilly, a drugmaker, as his government made decisions benefiting the company's obesity drugs business. The purchases coincided with favorable government decisions, including progress toward Medicare reimbursement for the drugs. Trump's investments were valued up to $680,000.

West Pharmaceutical Services was targeted by a cyberattack resulting in data theft and system encryption. The company disclosed the attack, which compromised its systems and led to data exfiltration. The incident highlights growing cybersecurity concerns in the pharmaceutical industry.

West Pharmaceutical Services reported a ransomware attack that breached their network on May 4, resulting in stolen data and encrypted systems. The company filed a report with the Securities and Exchange Commission warning customers of the incident. This attack is impacting West Pharmaceutical Services' business operations.